南财智讯7月27日电,石药集团(01093.HK)发布自愿公告,公司自主研发的1类创新药盐酸阿姆西汀肠溶片(HA1406)治疗抑郁症患者的III期临床试验(方案号:HA1406-007)已达成预设主要有效性终点,MADRS评分较基线变化值显著优于安慰剂(P<0.0001),且数值上优于阳性对照药;次要终点亦呈良好获益趋势,安全性良好。该药为新型强效选择性5-羟色胺/去甲肾上腺素双重再摄取抑制剂(...
Source Link南财智讯7月27日电,石药集团(01093.HK)发布自愿公告,公司自主研发的1类创新药盐酸阿姆西汀肠溶片(HA1406)治疗抑郁症患者的III期临床试验(方案号:HA1406-007)已达成预设主要有效性终点,MADRS评分较基线变化值显著优于安慰剂(P<0.0001),且数值上优于阳性对照药;次要终点亦呈良好获益趋势,安全性良好。该药为新型强效选择性5-羟色胺/去甲肾上腺素双重再摄取抑制剂(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.